Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.-Reference-Cited by-同舟云学术

Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.

Published:2023-07 Issue:32 Volume:41 Page:4666-4678
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Shoaibi Azadeh,Lloyd Patricia C.,Wong Hui-Lee^ORCID,Clarke Tainya C.,Chillarige Yoganand^ORCID,Do Rose^ORCID,Hu Mao,Jiao Yixin,Kwist Andrew,Lindaas Arnstein,Matuska Kathryn,McEvoy Rowan,Ondari Michelle^ORCID,Parulekar Shruti,Shi Xiangyu,Wang Jing,Lu Yun,Obidi Joyce,Zhou Cindy K.,Kelman Jeffrey A.,Forshee Richard A.^ORCID,Anderson Steven A.^ORCID

Funder

U.S. Food and Drug Administration

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference52 articles.

1. Centers for Disease Control and Prevention. Trends in Number of COVID-19 Cases and Deaths in the US Reported to CDC, by State/Territory; 2022; https://covid.cdc.gov/covid-data-tracker/#trends_weeklydeaths_select_00. Accessed 1/9/2023.

2. Centers for Disease Control and Prevention. New admissions of patients with confirmed COVID-19; 2023; https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions. Accessed 1/9/2023, 2023.

3. Centers for Disease Control and Prevention. Demographic trends of COVID-19 cases and deaths in the US reported to CDC; 2022; https://covid.cdc.gov/covid-data-tracker/#demographics. Accessed 1/9/2023.

4. Centers for Disease Control and Prevention. Overview of COVID-19 Vaccines; 2022; https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html. Accessed November 30, 2022.

5. U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccines; 2022; https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines. Accessed 1/9/2023.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Neurologic or Immune-Mediated Adverse Events After COVID-19 Diagnosis in the United States;2024-07-18

2. Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study;JMIR Public Health and Surveillance;2024-07-15

3. Risk of Adverse Events Following Monovalent Third or Booster Dose of COVID-19 mRNA Vaccination in U.S. Adults Ages 18 Years and Older;2024-02-27

4. COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic;Vaccine;2024-02